首页> 外文期刊>British Journal of Clinical Pharmacology >Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.
【24h】

Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.

机译:术后牙痛患者中COX-2抑制剂的疼痛缓解模型。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To develop a pain relief model for a cyclooxygenase (COX)-2 inhibitor, CS-706, that permits prediction of doses for acute pain relief in Japanese and Western populations. METHODS: A categorical response model was developed to describe the probability of pain relief (PR) over time for a Phase 2a study. Models were also developed to describe patient's use of rescue medication and onset of pain relief. RESULTS: The placebo response was described by a first-order increase in PR that achieved a stable response after 4 h. The effect of CS-706 on PR was described using an E(max) model; the plasma concentration of CS-706 producing 50% of the maximum response was estimated to be 87 ng ml(-1), the median peak plasma concentration achieved after a 50-mg oral dose. The probability of rescue medication (REMD) decreased over time and was a function of the last observed PR score. This probability was < 16% for patients with a PR score > or =2. The probability of experiencing meaningful PR was 98% in patients whodid not require REMD and 47% in those who required REMD. For patients who did not require REMD, the median onset time of meaningful pain relief (TMPR) decreased with increasing doses. In patients who required REMD, there was a saturable decline in TMPR, with the greatest improvement occurring from placebo to 50-mg doses. CONCLUSIONS: The set of models developed permitted compilation of multiple dose-response curves for dose selection of CS-706 in Westerners and facilitated scaling of doses to a Japanese population.
机译:目的:为环氧合酶(COX)-2抑制剂CS-706建立缓解疼痛的模型,该模型可以预测日本和西方人群急性缓解疼痛的剂量。方法:开发了分类反应模型来描述2a期研究随时间推移疼痛缓解(PR)的可能性。还开发了描述患者使用急救药物和缓解疼痛发作的模型。结果:安慰剂反应被描述为PR的一级增加,在4小时后达到稳定的反应。使用E(max)模型描述了CS-706对PR的影响;产生最大响应的50%的CS-706血浆浓度估计为87 ng ml(-1),这是口服50毫克后达到的中值峰值血浆浓度。抢救药物的可能性(REMD)随着时间的推移而降低,并且是最近一次观察到的PR评分的函数。对于PR评分>或= 2的患者,该概率为<16%。不需要REMD的患者发生有意义的PR的可能性为98%,而需要REMD的患者为47%。对于不需要REMD的患者,有意义的疼痛缓解(TMPR)的中位起效时间随着剂量的增加而减少。在需要REMD的患者中,TMPR出现饱和下降,从安慰剂到50 mg剂量的改善最大。结论:开发的模型集允许在西方人中选择CS-706的剂量选择的多个剂量反应曲线的汇编,并促进剂量的缩放到日本人口。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号